APO-Bortezomib bortezomib 3.5mg powder for injection vial

Riik: Austraalia

keel: inglise

Allikas: Department of Health (Therapeutic Goods Administration)

Toimeaine:

bortezomib, Quantity: 3.5 mg

Saadav alates:

Arrotex Pharmaceuticals Pty Ltd

INN (Rahvusvaheline Nimetus):

Bortezomib

Ravimvorm:

Injection, powder for

Koostis:

Excipient Ingredients: mannitol

Manustamisviis:

Subcutaneous, Intravenous

Ühikuid pakis:

1

Retsepti tüüp:

(S4) Prescription Only Medicine

Näidustused:

Bortezomib, in combination with melphalan and prednisone is indicated for the treatment of patients with previously untreated multiple myeloma who are not candidates for high dose chemotherapy.,Bortezomib, as part of combination therapy, is indicated for induction therapy prior to high dose chemotherapy with autologous stem cell rescue for patients under 65 years of age with previously untreated multiple myeloma.,Bortezomib is also indicated for the treatment of multiple myeloma patients who have received at least one prior therapy and who have progressive disease.

Toote kokkuvõte:

Visual Identification: White to off-white powder; Container Type: Vial; Container Material: Glass Type I Clear; Container Life Time: 24 Months; Container Temperature: Store below 25 degrees Celsius

Volitamisolek:

Licence status A

Loa andmise kuupäev:

2015-07-22